IGC Pharma, Inc. NYSE American: IGC

Caregiver burden is a critical dimension of Alzheimer’s disease Recognizing its scope helps inform better clinical priorities, including addressing symptoms like agitation that impact daily life Learn more about CALMA: igcpharma.com/calma/ #AlzheimersCare #AlzheimersDisease

As part of caregiver engagement efforts, IGC Pharma joined the caregiver-focused podcast Autumn Is Here to discuss agitation as a clinically significant symptom of Alzheimer’s disease Read more: finance.yahoo.com/sectors/health… #AlzheimersDisease #CaregiverSupport

Kerwin Medical Center in Dallas has been added as a clinical site in the ongoing Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer’s disease. Enrollment is now ~80%.  Read more: finance.yahoo.com/sectors/health… #AlzheimersResearch

IGC Pharma has received authorization in Colombia to synthesize, formulate, and conduct development activities involving psilocybin at its research and development facility in Bogotá. Read More: finance.yahoo.com/sectors/health… #AlzheimersDisease #ClinicalResearch

Initiatives like aha™ (Agentic Harmonization Assistant) are designed to help address this integration challenge Advancing science requires integration at scale Learn more: igcpharma.com/aha-agentic-ha… #AIinHealthcare #DataScience #ResearchInfrastructure

Harmonization isn’t just a technical task It’s research infrastructure Scalable, interoperable data systems are essential to accelerating Alzheimer’s discovery ⬇️

#AlzheimersResearch depends on clinical, imaging, and biomarker data collected across institution But these datasets often use different formats, encodings, and standards They don’t automatically “speak the same language” ⬇️

Agitation is one of the most challenging symptoms associated with Alzheimer’s. IGC Pharma is developing investigational therapeutic approaches targeting this unmet need through rigorous clinical development. Watch: youtube.com/watch?v=PPY2CK… #AlzheimersResearch

IGC Pharma reports ~80% enrollment in its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer’s disease.  Enrollment completion is expected mid-2026 as the study enters its final recruitment phase. Read More: finance.yahoo.com/sectors/health… #AlzheimersResearch

IGC Pharma CEO Ram Mukunda joined @NewToTheStreet to discuss Alzheimer’s disease, agitation, and the ongoing Phase 2 CALMA trial evaluating IGC-AD1, along with recruitment efforts and what comes next. Watch the full interview: youtube.com/watch?v=1qG4yD… #AlzheimersResearch

Ascendiant Capital Markets has issued an updated equity research report on the Company, raising its price target to $5.25 per share.  Read more: finance.yahoo.com/sectors/health… #IGCPharma #EquityResearch #CapitalMarkets #NYSEAmerican

On #WorldHealthDay, we bring attention to a growing reality: Alzheimer’s continues to expand worldwide, while disparities in diagnosis and research participation persist Sustainable progress depends on closing those gaps #GlobalHealth #AlzheimersResearch

Tandem Clinical Research (@ClinicalTandem) has been activated as a new site for IGC Pharma’s Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer’s dementia. Enrollment is now over 70% complete.  Read more: finance.yahoo.com/sectors/health… #AlzheimersResearch #IGCPharma

IGC Pharma has partnered with @NewToTheStreet. The campaign includes sponsored programming on Fox Business and Bloomberg Television, along with digital and outdoor distribution Read more: finance.yahoo.com/sectors/health… #IGCPharma #InvestorRelations

🧬 IGC Pharma Partners with New to The Street! @IGCIR (NYSE American: IGC), focused on Alzheimer’s therapeutics, announces a strategic 12-part national media partnership with New to The Street. @vincemedia1 The multi-channel campaign includes long-form interviews, national TV commercials, digital amplification, and high-visibility outdoor placements, boosting visibility across institutional and retail investors. 🚀 💡 Driving awareness. Elevating innovation. READ HERE⬇️⬇️⬇️ bit.ly/IGCPharmapress… Watch the Newsout feature here⬇️⬇️⬇️ bit.ly/NTTS-NEWSOUT-N… Learn more at investor.igcpharma.com #IGCPharma #Media #Biotech #Innovation #NewToTheStreet

New to The Street x IGC Pharma Partnership! @NewToTheStreet and @IGCIR (NYSE American: IGC) launch a strategic 12-part national media partnership to boost investor awareness and strengthen market positioning. @vincemedia1 💡 Expanding reach. Elevating visibility. READ HERE⬇️⬇️⬇️ bit.ly/NewtoTheStreet… Watch the Newsout feature here⬇️⬇️⬇️ bit.ly/NTTS-NEWSOUT-N… Learn more at investor.igcpharma.com #IGCPharma #Media #Biotech #Innovation #NewToTheStreet

The CALMA Clinical Trial team joined the Autumn Is Here podcast hosted by Francine Crawford to discuss agitation in Alzheimer’s disease, trial safety, and what researchers hope to learn Listen to the full episode: youtube.com/watch?v=uXguYF… #AlzheimersAwareness #CaregiverSupport

Live from #ADPD2026: the IGC Pharma AI team presented aha™ at the ADDI (@AlzData) booth aha™ supports scalable harmonization of tabular and neuroimaging datasets, strengthening the foundation for AI-driven Alzheimer’s research. #AIinHealthcare

IGC Pharma filed its Form 10-KT for the 9 months ended Dec 31, 2025, reflecting clinical acceleration, expansion of the Phase 2 CALMA trial, and improved net loss dropping to $4.1M vs. $5.9M in the prior year.   Read More: finance.yahoo.com/sectors/health… #InvestorRelations